Table 4.
Baseline | 60-day | p-valuea | 6-month | p-valuea | 12-month | p-valuea | |
---|---|---|---|---|---|---|---|
NumDU (frequency) | |||||||
Control (n = 14) | 7.5 | 3.0 | 0.24 | 6.0 | 0.02 | 4.0 | 0.12 |
MI-only (n = 12) | 12.0 | 0.0 | 0.0 | 3.0 | |||
MI+HealthCall (n = 13) | 9.0 | 5.0 | 2.0 | 1.0 | |||
QuantU (quantity) | |||||||
Control (n = 14) | 10.7 | 3.3 | 0.77 | 7.8 | 0.04 | 4.3 | 0.11 |
MI-only (n = 12) | 17.1 | 0.0 | 0.0 | 2.0 | |||
MI+HealthCall (n = 13) | 18.2 | 8.5 | 5.3 | 0.8 |
p-Value from Kruskal-Wallis test of whether there are treatment group differences in reduction of drug use between baseline and 60-day, 6-month, or 12-month follow-up.